This inventor holds 6 USPTO granted patents. Top assignees: Eniricerche S.p.a., Sigma-Tau Industrie Farmaceutiche, Sigma-Tau Industrie Farmaceutiche Riunite S.p.a.. Active years: 1990-2013.
Location History:
- Pomezia, IT (2008)
- Rome, IT (1990 - 2013)
Company Filing History:
4 out of 260 
1 out of 2 
1 out of 343 
Years Active: 1990-2013
Title: The Innovative Contributions of Carlo A. Nuzzolo
Introduction
Carlo A. Nuzzolo is a prominent inventor based in Rome, Italy. He has made significant contributions to the field of biochemistry and medical therapies, holding a total of 6 patents. His work focuses on the development of modified avidins that enhance therapeutic applications.
Latest Patents
One of his latest patents is titled "Oxidized avidin with high residency time in the treated tissues." This invention describes chemically modified avidins that exhibit greater permanence in treated tissues compared to wild type avidin. The oxidation process involves periodate incubation in the presence of the low affinity ligand HABA, which occupies the biotin binding sites and prevents protein denaturation during oxidation. The resulting CHO groups from avidin mannose ring opening react with tissue NH residues to form stable Schiff's bases. These anchored avidins retain the ability to bind biotinylated agents with therapeutic activity, such as radiolabeled biotins and stem cells, which are useful for brachytherapies like Intraoperative Avidination Radionuclide Therapy (IART®) or for treating degenerative and genetic diseases.
Another notable patent is "Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy." This patent describes dimers of avidin and streptavidins (diavidins) that utilize a suberate linker bound to various functional groups of avidin. Compared to avidin, these diavidins have demonstrated an increased ability to enhance the amount of labeled biotin on the target in in vitro pretargeting tests. Their application extends to cancer diagnosis and anticancer therapy based on a three-step pretargeted radioimmunotherapy procedure.
Career Highlights
Throughout his career, Carlo A. Nuzzolo has worked with notable companies such as Eniricerche S.p.a. and Sigma-Tau Industrie Farmaceutiche Riunite S.p.a. His innovative work has positioned him as a key figure in the development of advanced therapeutic techniques.
Collaborations
He has collaborated with esteemed colleagues, including Adriano Bernardi and Antonello Pessi, contributing to the advancement of biochemistry and medical therapies.
Conclusion
Carlo A. Nuzzolo's contributions to the field of biochemistry through his innovative